Chromosome instability (CIN) is one of the most important phenotypes in tumor progression, introducing multiple mutations required for acquisition of further malignant characteristics. Abnormal amplification of centrosomes, which is frequently observed in human cancer, has been shown to contribute to CIN by increasing the frequency of mitotic defects. Here, we show that transient exposure to subtoxic concentrations of commonly used anticancer drugs that target DNA synthesis induces centrosome amplification in cells lacking p53 tumor suppressor protein, by allowing continuous centrosome duplication in the absence of DNA synthesis. When these cells are released from cell cycle arrest by removal of drugs, cells suffer extensive destabilization of chromosomes. Considering that p53 is the most frequently mutated gene in human cancer and that CIN is known to be associated with acquisition of malignant phenotypes, our observations may explain why recurrent tumors, after chemotherapy, often exhibit more malignant characteristics than the original tumors. The tumor cells that are exposed to subtoxic levels of DNA synthesis-targeting drugs will be arrested and undergo centrosome amplification. Upon cessation of chemotherapy, these cells will reenter cell cycling, and experience extensive CIN due to the presence of amplified centrosomes. This in turn promotes generation of tumor cells equipped with further malignant characteristics.
Oncogene ( Keywords: centrosome amplification; chromosome instability; p53; DNA synthesis; anticancer drug Chromosome instability (CIN) is considered one of the most formidable forces driving tumor progression. The loss or gain of a single chromosome could introduce multiple genetic alterations required for acquisition of malignant phenotypes. Centrosome amplification, which occurs frequently in human cancers, is believed to contribute to CIN by causing abnormal mitotic processes and thus increasing the frequency of chromosome transmission errors (Brinkley and Goepfert, 1998; D'Assoro et al., 2002) .
The centrosome is a small nonmembranous organelle, consisting of a pair of centrioles and a number of different proteins (pericentriolar material) surrounding the centriole pair (Lange and Gull, 1996) . The centrosome serves as a major microtubule-organizing center of animal cells, and plays a key role in establishing bipolar spindles during mitosis as a core component of a spindle pole, which is essential for balanced segregation of chromosomes into two daughter cells (Doxsey, 2001; Fukasawa, 2002) . Since each daughter cell receives only one centrosome from the parent cell upon cytokinesis, the centrosome, like DNA, needs to duplicate prior to the next mitosis, and must do so only once in a single cell cycle. Thus, in any given time point, cells normally have either one or two centrosomes depending on whether the centrosome is in the pre-or postduplication stage, and this numeral integrity of centrosomes is highly controlled; probably by multiple mechanisms (Fukasawa, 2002) . Abrogation of such control mechanisms results in abnormal amplification of centrosomes (X3 centrosomes). For instance, loss of the regulation that suppresses reduplication of centrosomes leads to multiple duplication of centrosomes within a single cell cycle, resulting in centrosome amplification (Tarapore and Fukasawa, 2002) . Another example is that progression into the next cell cycle without cytokinesis, caused by either internal or external insults, results in the doubling of centrosome numbers as well as genome contents (Meraldi et al., 2002) . The presence of more than two centrosomes results in high frequencies of aberrant mitotic spindle formation, which in turn increases the frequency of unequal segregation of chromosomes or CIN.
It has previously been shown that administration of DNA synthesis inhibitors such as aphidicolin (Aph: inhibitor of DNA polymerase) and hydroxyurea (HU: inhibitor of ribonucleotide reductase) uncouples centrosome and DNA duplication. Normally, initiation of centrosome and DNA duplication occur concomitantly (Mazia, 1987; Vandre and Borisy, 1989) . However, administration of these DNA synthesis inhibitors results in continuous centrosome duplication without DNA synthesis, leading to centrosome amplification (Balczon et al., 1995) . It was later found that this phenomenon occurs when p53 tumor suppressor protein is either mutationally inactivated or lost (Tarapore et al., 2001; Nayak and Das, 2002) . The cellular stress imposed by Aph or HU triggers a checkpoint machinery that leads to the stabilization/functional activation of p53, which upregulates p21 waf1/cip1 , a known CDK inhibitor (CKI) and major target of p53's transactivation function (el-Deiry et al., 1993; Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993) . Expression of high levels of p21 waf1/cip1 suppresses the activity of CDK-cyclin kinase complexes, including CDK2/cyclin E, a kinase complex responsible for initiation of centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999) . Thus, in the presence of p53, Aph-or HU treatment halts DNA duplication as well as centrosome duplication. On the other hand, in the absence of p53, Aph-or HU treatment only blocks DNA synthesis, but not centrosome duplication (Tarapore et al., 2001) .
It is known that recurrent tumors arising after remission from chemotherapeutic treatment are frequently more malignant than the original tumors (i.e., higher metastasis potential). Since the acquisition of malignant phenotypes is often associated with CIN (Cheng and Loeb, 1993) , one explanation is that some cancer cells that survive through chemotherapeutic regimens might have either acquired a CIN phenotype or worsened pre-existing CIN phenotype. Many of the anticancer drugs currently used in chemotherapeutic protocols target DNA synthesis, some of which may induce centrosome amplification similar to Aph and HU. Thus, it is reasonable to hypothesize that upon exposure to S-phase-targeting anticancer drugs, certain population of cells within a tumor may experience subtoxic levels of the drugs. In these cells, centrosomes may continue to duplicate while DNA synthesis is halted. Upon cessation of the drug treatment, these cells re-enter the cell cycle in the presence of amplified centrosomes, which destabilizes chromosomes, promoting the acquisition of further malignant phenotypes. In this study, we tested this hypothesis by transiently treating adult skin fibroblasts derived from mice lacking p53 (p53 À/À MSFs) with subtoxic concentrations of commonly used S-phase-targeting anticancer drugs. We found that administration of these drugs (actinomycin D (Act-D), arabinoside C (Ara-C), 5-fluorouracil (5-FU)) all result in centrosome amplification. Moreover, the drug-treated cells, which were allowed to undergo several cell cycles after removal of drugs, showed destabilization of chromosomes, resulting in extensive karyotypic heterogeneity.
Since the administration of DNA synthesis inhibitors such as Aph or HU results in centrosome amplification only when p53 is either mutationally inactivated or lost, we decided to use cells derived from mice lacking p53 (p53 À/À mice) for examination of the effects of S-phasetargeting chemotherapeutic drugs on numeral homeostasis of centrosomes. It is known that loss of p53 alone induces centrosome amplification in mouse cells:
20-30% of early passage p53
À/À mouse cells show centrosome amplification (Fukasawa et al., 1996) . Thus, these early passage p53 À/À mouse cells are karyotypically heterogeneous due to amplified centrosomes (Chiba et al., 2000) . Although depending on the protocol used for preparation of primary cell cultures, 30-50% of p53 À/ À fibroblasts either of embryonic origin or of adult skin prepared are typically found euploid (2N ¼ 40) and the rest are found aneuploid (both hypoploid and hyperploid). For our study, we decided to use p53 À/À MSFs. The drugs used in this study were actinomycin D (Act-D: DNA-binder), arabinoside-C (Ara-C: pyrimidine nucleoside analog), and 5-fluorouracil (5-FU: thymidine production inhibitor), all of which were commonly administered as anticancer drugs. To establish an in vitro model system, we first determined the concentration of each drug that would neither irreversibly arrest the majority of cells nor force them to commit to a cell death pathway. To this end, p53
MSFs were first seeded on coverslips at a subconfluent density. After 24 h, drugs were added to the media with various concentrations. Then, the drugs were completely removed from the media after 24 h treatment, and cells were incubated in fresh media containing bromodeoxyuridine (BrdU) for 1 h. BrdU incorporation was determined by immunocytochemistry using an antiBrdU antibody (Figure 1 ). For each drug concentration, we determined the percent of cells that either initiated or resumed DNA synthesis (BrdU-positive cells) relative to the number of cells initially seeded on coverslips (Figure 1) . The reason for the use of the initially seeded number of cells as a denominator is that all the drugs used here induce rapid cell death at higher concentration, resulting in detachment of cells from a coverslip surface, and our attempt is to determine the concentration of drugs that reversibly arrests the cells, but does not trigger cell death. From the toxicity curve based on drug concentration and further detailed testing of the concentration ranges that induced sharp decreases in percent of BrdU-positive cells (Act-D: 0-20 mM, Ara-C: 0-20 mM, 5-FU: 0-10 mM) (data not shown), we set the subtoxic concentration of each drug, which reversibly arrest 80-90% of p53 À/À MSFs, as Act-D: 10 mM, Ara-C: 5 mM, and 5-FU: 7.5 mM.
To determine whether exposure to subtoxic concentration of the DNA synthesis-targeting anticancer drugs leads to centrosome amplification in p53 À/À MSFs, cells were incubated in the media containing subtoxic concentrations of Act-D, Ara-C, and 5-FU for 24 h, and examined for centrosomes by immunostaining gtubulin, a major centrosomal protein (Oakley, 1996) (Figure 2a , representative microscopic images are shown in Figure 2b ). In all, 20-30% of the control untreated p53 À/À MSFs contained amplified (X3) centrosomes. In contrast, 490% of cells treated with Act-D and Ara-C and 470% of cells treated with 5-FU contained amplified centrosomes.
Since g-tubulin is localized in the pericentriolar material (Stearns et al., 1991) , g-tubulin immunostaining normally does not distinguish each individual centriole within the centrosome. Since centrosome amplification is occasionally accompanied with splitting of a centriole pair (Fukasawa, 2002) , we examined the integrity of amplified centrosomes by coimmunostaining cells with anti-g-tubulin (polyclonal) and anti-b-tubulin (monoclonal) antibodies. The control untreated and drugtreated cells were subjected to cold treatment (for destabilization of microtubules nucleated at the centrosome) and brief extraction (for removal of depolymerized tubulins) (for a detailed procedure, see the legend to Figure 3 ). Cells were then fixed and immunostained (Figure 3) . Anti-g-tubulin antibody detected each of amplified centrosomes as a single dot (panels b, e, h). Since b-tubulin is one of the major constituents of centrioles, immunostaining of b-tubulin (panels a, d, g) allows visualization of centrioles within the centrosome at a high magnification (panels a-i). The majority (70-80%) of anti-g-tubulin antibody-reactive dots contained paired centrioles (two juxtaposing anti-b-tubulin-reactive dots: panels b-g), while some (10-20%) contained only one centriole (panel i), suggesting that minor population of the amplified centrosomes may be generated through centriole splitting. Normally, centriole splitting occurs only when the centrosome initiates duplication, remaining a close distance to each other (the separated centriole pairs probably prior to procentriole formation is shown in panel h). However, many of the unpaired centrioles found in cells with amplified centrosomes were found dispersed (panel i, showing four dispersed unpaired centrioles). Generation of these dispersed unpaired centrioles appeared to be associated with centrosome amplification per se, since this phenomenon is almost exclusively found in cells with a high degree of centrosome amplification (panels g-i). Moreover, the dispersed unpaired centrioles are most likely not caused by exposure to the drugs, since they can be readily found in untreated p53 À/À MSFs with extensive centrosome amplification. In sum, we conclude that, similar to Aph and HU, transient exposure to subtoxic concentration of DNA synthesis-targeting anticancer drugs results in centrosome amplification.
We next examined whether an increased frequency of centrosome amplification in the drug-treated p53 À/À MSFs would be translated to destabilization of chromosomes. p53 À/À MSFs were transiently treated with subtoxic concentrations of the DNA synthesis-targeting drugs for 24 h, followed by removal of the drug and incubation in fresh media for 5 days, which allows recovery from drug exposure and several cell cycles. We then prepared metaphase spreads for fluorescence in situ hybridization (FISH) analysis using a centromeric chromosome probe, and a number of chromosomes per cell was counted under a fluorescence microscope. Although this method of chromosome counting is known to be accurate, it is not completely devoid of À/À MSFs. p53 À/À MSFs were prepared from abdominal skins of 8-week-old male mice deficient of p53 (Taconic Farm) as described previously (Chen et al., 1983) . Exponentially growing p53 À/À MSFs (passage 5) on coverslips were exposed to various concentrations of actinomycin D (Act-D), arabinoside C (Ara-C), 5-fluorouracil (5-FU) for 24 h. At the end of treatment, cells were washed several times with PBS and fed with complete media (DMEM supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg/ml)) containing BrdU for 1 h. Cells were then processed for immunostaining using the 5-bromo-2 0 -deoxy-uridine labeling and detection kit I (Boehringer Mannheim) according to the manufacturer's instruction. Briefly, cells were fixed in 70% ethanol in 50 mM glycine (pH 2.0) for 20 min at 251C and probed with anti-BrdU monoclonal antibody for 30 min at 371C, followed by detection with FITC-conjugated sheep anti-mouse IgG. The number of BrdU-incorporated cells was determined under a fluorescence microscope. The data shown are the percent of BrdU-incorporated cells in relation to the number of cells initially seeded on coverslips. With further testing, we set the subtoxic concentration of each drug as Act-D: 10 mM, Ara-C: 5 mM, and 5-FU: 7.5 mM Induction of centrosome amplification by anticancer drugs RA Bennett et al À/À MSFs on coverslips were exposed to either Act-D (10 mM), Ara-C (5 mM), or 5-FU (7.5 mM) for 24 h. Cell were then fixed with 10% formalin/10% methanol for 20 min at 251C, permeabilized with 1% NP-40 in phosphate-buffered saline (PBS) for 5 min, followed by incubation with blocking solution (15% normal goat serum in PBS) for 1 h. Cells were then probed with rabbit anti-g-tubulin polyclonal antibody for 1 h, and antibody-antigen complexes were detected with Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody (Molecular Probes) by incubation for 1 h at 251C. The cells were washed three times with PBS after each incubation and then counterstained with 4 0 , 6-diamidino-2-phenylindole (DAPI). Immunostained cells were examined under a fluorescence microscope (Nikon Microphot-FX) using a 60 Â objective lens. The fluorescent images were captured with SPOT camera (Diagnostic Instruments Inc.). For each sample, 4100 cells were examined. panels a, d, g ) and anti-g-tubulin polyclonal antibodies (green) (panels b, e, h). For immunostaining, cells were first incubated on ice for 30 min (destabilizes microtubules nucleated at the centrosomes), followed by a brief extraction (B15 s) with cold extraction buffer (0.75% Triton X-100, 5 mM Pipes, 2 mM EGTA (pH 6.7)). Cells were then briefly washed in cold PBS, and fixed with 10% formalin/10% methanol for 20 min at 41C, followed by permiabilization and blocking as described in the legend to À/À MSFs were exposed to either Act-D (10 mM), Ara-C (5 mM), or 5-FU (7.5 mM) for 24 h. At the end of treatment, cells were washed several times with PBS, fed with fresh complete media, and incubated for 5 days. Metaphase spreads were then prepared from untreated and drug-treated cells as described previously (Carroll et al., 1999; Izumi et al., 2002) . Briefly, cells were incubated in the presence of colcemid (0.5 mg/ml) for 4 h to enrich mitotic cells. The medium containing rounded-up mitotic cells was saved. The remaining cells were trypsinized, and together with the saved medium, cells were pelleted by centrifugation. The cells were gently resuspended in hypotonic solution (0.075 M KCl) at 371C for 15 min. After removal of the hypotonic solution, a methanol-acetic acid fixative was added, and cells were allowed to stand for 10 min. The old fixative was discarded and fresh fixative was added. This procedure was repeated two more times. After the last change of fixative, metaphase spreads were prepared on positively charged microscope slides. Cy3-labeled centromeric DNA probe (Mouse Pan-Centromeric Chromosome Paint, Cambio) prepared according to the manufacturer's instruction was added to the slide, and a coverslip was laid on top. The slides were then placed in a humidified staining chamber for 16 h, followed by washing in prewarmed (371C) 2 Â SSC for 5 min, followed by washing twice in prewarmed 2 Â SSC/50% formamide for 5 min at 371C. Slides were then washed twice in prewarmed 2 Â SSC for 5 min at 371C. DAPI DNA dye was added on slides for 10 min at room temperature, followed by gentle wash with 2 Â SSC. All the FISH procedures were performed in the dark. The number of chromosomes per cell was scored by fluorescence microscopy. Owing to the expected errors of this procedure as described in the text, we allowed a 72 deviation for chromosome counting. The studies presented here show that many of anticancer drugs that target DNA synthesis can induce centrosome amplification when administered at subtoxic concentrations. Upon removal of drugs, cells that have escaped irreversible cell cycle arrest or cell death re-enter the cell cycle and undergo mitotic cell division. The presence of more than two centrosomes results in the formation of aberrant spindles, which in turn increases the frequency of chromosome transmission errors. Despite the continuous improvement of the anticancer drug delivery method, it is of great difficulty to expose all tumor cells to the maximal or most effective concentrations of drugs. Considering the fact that p53 is the most frequently mutated gene in human cancer (Hollstein et al., 1991; Levine et al., 1991; Harris, 1996) , cancer cells that have been exposed to a subtoxic concentration of the drug that targets DNA synthesis likely experience centrosome amplification. Upon cessation of chemotherapy, those cells will resume cell cycling. Owing to the presence of amplified centrosomes, chromosomes will be destabilized, which promotes the acquisition of further malignant phenotypes. This may be at least one of the reasons for recurrent tumors after chemotherapy often found to be more malignant than original tumors. Although our studies were carried out in cultured cells, and needs to be further tested in mouse model systems, our findings strongly support the above scenario. Many anticancer drugs that target DNA synthesis have been found to be very effective, and there is little doubt that DNA synthesis is a major target for future development of more effective drugs. However, the possibility that DNA synthesis-targeting drugs may exacerbate a CIN phenotype by inducing centrosome amplification should be taken into account.
